Compare Abeona Therapeutics Inc (ABEO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while YieldMax NVDA Option Income Strategy ETF trades at $12.6. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | NVDY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $17.96 |
52-Week Low | $4.17 | $12.03 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NVDY trades at $12.19, up 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The fund generates weekly dividends from its covered call strategy on NVIDIA, with recent payouts ranging from $0.10 to $0.21 per share. News highlights debate whether the income strategy justifies sacrificing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums; risks include capped gains during NVIDIA rallies. The 1.09% fee and opportunity cost versus direct NVIDIA ownership are key considerations for income-focused investors amid bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
